A Novel Treatment With Obinutuzumab-Chlorambucil in a Patient With B-Cell Prolymphocytic Leukemia: A Case Report and Review of the Literature-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Novel Treatment With Obinutuzumab-Chlorambucil in a Patient With B-Cell Prolymphocytic Leukemia: A Case Report and Review of the Literature

Published:2018-01 Issue: Volume:6 Page:232470961878867
ISSN:2324-7096
Container-title:Journal of Investigative Medicine High Impact Case Reports
language:en
Short-container-title:Journal of Investigative Medicine High Impact Case Reports

Author:

Hew Jason¹,Pham Dat¹,Matthews Hew Trevanne¹,Minocha Vinay¹

Affiliation:

1. University of Florida, Jacksonville, FL, USA

Publisher

SAGE Publications

Subject

Safety Research,Safety, Risk, Reliability and Quality,Epidemiology

Link

http://journals.sagepub.com/doi/pdf/10.1177/2324709618788674

Reference13 articles.

1. Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper

2. How I treat prolymphocytic leukemia

3. Obinutuzumab

4. Management of prolymphocytic leukemia

5. Targeted therapies for CLL: Practical issues with the changing treatment paradigm

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. De-Novo B-Cell Prolymphocytic Leukemia;Journal of Hematology;2023-04

2. A new case of trisomy 5 with complex karyotype abnormalities in B-cell prolymphocytic leukemia: a case study;Egyptian Journal of Medical Human Genetics;2022-03-03

3. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics;Genes & Diseases;2022-03

4. An illustrative case of B-cell prolymphocytic leukemia;BLOOD RESEARCH;2020-09-30

5. Rituximab;Reactions Weekly;2018-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP